Production of ROS by Gallic Acid Activates KDM2A to Reduce rRNA Transcription

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Metformin exhibits anti-cancer properties by activating KDM2A, inhibiting rRNA transcription and cancer cell proliferation.
• KDM2A activation presents a potential therapeutic strategy for various cancers.

Purpose of the Study:

• To identify compounds that modulate cancer cell proliferation by screening a food-additive library.
• To investigate the mechanism by which gallic acid affects KDM2A activity and cancer cell growth.

Main Methods:

• Screening of a food-additive compound library against breast cancer MCF-7 cells.
• Assessing KDM2A activation, rRNA transcription, cell proliferation, ROS production, and AMPK activity.
• Comparing gallic acid's mechanism with metformin's KDM2A activation pathway.

Main Results:

• Gallic acid activated KDM2A, leading to reduced rRNA transcription and proliferation in MCF-7 cells.
• Gallic acid-induced KDM2A activation required ROS production and AMPK activation, distinct from metformin's succinate-dependent pathway.
• Gallic acid did not inhibit proliferation in non-tumorigenic MCF10A cells, suggesting cancer-specific effects.

Conclusions:

• Gallic acid activates KDM2A through ROS and AMPK signaling, offering a novel anti-cancer mechanism.
• The distinct pathways for KDM2A activation by gallic acid and metformin highlight the convergence of intracellular signals.
• Gallic acid's KDM2A-mediated anti-proliferative effect in breast cancer cells suggests therapeutic potential.